Prostate health assessment (PHI)
Clarifying diagnostics of prostate gland diseases. Increases accuracy of prostate cancer detection compared to PSA alone.
What the test evaluates:
- Total PSA — overall prostate-specific antigen level in blood
- Free PSA — antigen fraction not bound to blood proteins
- -2proPSA — PSA isoform more specific to prostate cancer
- PHI (Prostate Health Index) — combined indicator increasing early malignant process detection accuracy
Biomaterial: Venous blood
- Draw blood fasting
- Abstain from ejaculation at least 48 hours before
- Exclude prostate massage, transrectal ultrasound, cystoscopy 7 days before
Medications:
- Hormonal therapy and prostate treatment drugs may affect results
- Inform physician of all medications taken
- Medication discontinuation only by physician prescription
Recommended for:
- Differential diagnosis of prostate diseases
- Suspected prostate cancer
Results evaluated by physician considering clinical data, ultrasound, and digital rectal examination.
Normal: PSA and PHI indicators within reference values; low probability of malignant process
Elevated values: may indicate prostate cancer; possible in benign hyperplasia, prostatitis, or after instrumental procedures; PHI increases diagnostic specificity and helps reduce unnecessary biopsies
Any deviation requires further examination and physician interpretation.
